New analysis of pooled data has provided more reassurance that the SGLT2 inhibitor canagliflozin is not associated with a higher risk of limb amputations, Australian researchers say. The concern about amputation risk was raised years ago in CANVAS trial findings – and reported here in the limbic – but has not been reproduced in subsequent ...
Amputation risks re-assessed for ‘cardioprotective’ SGLT2 inhibitors
By Mardi Chapman
4 Jun 2020